Tapentadol PR

DRUG3 trials

Sponsors

Janssen Pharmaceutical K.K., Grünenthal GmbH

Conditions

CancerChronic PainLow Back PainOsteoarthritisPain

Phase 2

Phase 2 Study of Tapentadol Prolonged Release in Cancer Pain Participants

CompletedNCT00805142

Janssen Pharmaceutical K.K.Cancer, Pain

Start: 2008-11-30End: 2009-07-31Updated: 2013-07-29

Phase 3

Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Pain Due to Osteoarthritis Taking WHO Step III Analgesics But Showing a Lack of Tolerability.

TerminatedNCT00982280

Grünenthal GmbHChronic Pain, Osteoarthritis

Start: 2009-09-30End: 2010-08-31Updated: 2019-10-18

Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics

CompletedNCT00983385

Grünenthal GmbHChronic Pain, Low Back Pain

Start: 2009-09-30End: 2010-07-06Updated: 2019-01-15

Related Papers

Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis pain.

2013-09-0138 citations

Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study.

2012-05-0962 citations